US › Healthcare

Lineage Cell Therapeutics Inc (LCTX)

US · Healthcare · Biotechnology

$1.12+0.90%

Last close · 2026-08-04

Latest quarter · ended 2026-03-31

Revenue

$1.7M

Revenue YoY

+14.8%

Net profit

$-4.8M

Profit YoY

-16.3%

EPS

$-0.03

EPS estimate

$-0.02

Net margin

-279.0%

EPS came in at -0.03 against a street estimate of -0.02 — a miss of 36.5%.

Key statistics

Market cap

$269.2M

Forward P/E

30.7

P/B

5.00

Book value

$0.22

EPS (TTM)

$-0.29

52-week high

$2.09

52-week low

$0.95

50-day MA

$1.23

200-day MA

$1.55

Beta

1.51

Analyst view

Analysts rate Lineage Cell Therapeutics Inc a buy (6 buy, 1 hold, 0 sell out of 7) with an average price target of $5.50.

Shareholding

Insiders

4.93%

Institutions

48.01%

See the full picture

Technicals, trade setups with a published hit rate, $AI analysis and earnings-call summaries for Lineage Cell Therapeutics Inc — free to start.

Google Play App Store

Other Healthcare companies

Eli Lilly and Company Johnson & Johnson AbbVie Inc UnitedHealth Group Incorporated Merck & Company Inc Novartis AG ADR AstraZeneca PLC Thermo Fisher Scientific Inc Novo Nordisk A/S Amgen Inc Abbott Laboratories Gilead Sciences Inc

Data updated 2026-08-05.